Trial Profile
Early retinal morphological changes in patients with Neovascular Age-Related Macular Degeneration treated with Bevacizumab, Ranibizumab, and Aflibercept
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 20 Feb 2018 New trial record
- 01 Jan 2018 Results published in the Ophthalmologica